BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//UCLA - ECPv5.14.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:UCLA
X-ORIGINAL-URL:https://www.chemistry.ucla.edu
X-WR-CALDESC:Events for UCLA
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20220215T160000
DTEND;TZID=America/Los_Angeles:20220215T160000
DTSTAMP:20260614T193539
CREATED:20220211T183814Z
LAST-MODIFIED:20220211T183814Z
UID:13604-1644940800-1644940800@www.chemistry.ucla.edu
SUMMARY:Chemical Strategies for Regulating DNA-Interactive Proteins: Targeting APOBEC Cytosine Deaminases and the N-Myc Transcription Factor
DESCRIPTION:Abstract: Our laboratory focuses on the development of small molecule ligands and enzymatic inhibitors of proteins that interact with nucleic acids. We utilize biophysical and biochemical assays to screen chemical libraries to discover protein-binding ligands\, which are then optimized using iterative rounds of molecular design\, synthesis\, and biological evaluation. Our overarching goals are to develop chemical probes to enable the discovery of new biology by the biomedical research community\, as well as develop novel and patentable therapeutic compounds for clinical development by a pharmaceutical partner. In this vein\, two programs from our laboratory\, the discovery of APOBEC inhibitors and N-Myc degraders\, will be presented. \nAPOBEC enzymes are a family of 7 human DNA cytosine-to-uracil deaminases that degrade foreign DNA as part of the innate immune response to pathogen infection. However\, APOBEC enzymes have been shown to contribute C-to-U/T mutations that enable virus and cancer cell genomic mutations that confer resistance to drug therapies. Consequently\, small molecule APOBEC inhibitors may have utility as “anti-mutation” therapies that slow or prevent the evolution of resistance mutations that defeat targeted drug therapies. Our work to develop first-in-class APOBEC inhibitors will be presented. \nThe Myc family of transcription factors are master regulators of proliferation in the majority of human cancers. In the case of childhood neuroblastomas\, which are the most prevalent cancer in children under 1-year of age\, N-Myc is a validated therapeutic target and molecular diagnostic. A vulnerability of N-Myc in many neuroblastomas is that N-Myc is stabilized from proteolytic degradation by Aurora kinase A (Aurora-A). We have developed novel chemical degraders of Aurora-A\, such as HLB-0532259\, that elicit the degradation of Aurora-A and the concomitant degradation of N-Myc. HLB-0532259 also exhibits potent antiproliferative activity in neuroblastoma cells and xenograft mouse models. Our work to develop novel N-Myc degraders will be presented.
URL:https://www.chemistry.ucla.edu/seminars/chemical-strategies-regulating-dna-interactive-proteins-targeting-apobec-cytosine/
CATEGORIES:Organic Colloquium,Seminars
END:VEVENT
END:VCALENDAR